Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Janssen Pharmaceutica Nv
Janssen Pharmaceutica Nv A Corporation
Janssen Pharmaceutica Nv_20131212
Janssen Pharmaceutica Nv_20100107

Janssen Pharmaceutica Nv patents


Recent patent applications related to Janssen Pharmaceutica Nv. Janssen Pharmaceutica Nv is listed as an Agent/Assignee. Note: Janssen Pharmaceutica Nv may have other listings under different names/spellings. We're not affiliated with Janssen Pharmaceutica Nv, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "J" | Janssen Pharmaceutica Nv-related inventors


 new patent  Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same

The present invention relates to certain intermediates useful in the preparation of certain benzoimidazol-2-yl pyrimidines and processes for preparing them. In particular, the present invention relates to various 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides as useful intermediates in the preparation of compounds including... Janssen Pharmaceutica Nv

 new patent  Substituted hydantoin and thiohydantoin derivatives as androgen receptor antagonists

wherein R1, R2a, R2b, Z, X, Y, and G are defined herein.... Janssen Pharmaceutica Nv

 new patent  Synthesis of a bruton?s tyrosine kinase inhibitor

Described herein is the synthesis of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo [3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.... Janssen Pharmaceutica Nv

Dispersible compositions

The present invention is concerned with dispersible compositions comprising bedaquiline fumarate as an active ingredient. Such compositions are useful in the treatment of tuberculosis and their inherent dispersibility properties lend themselves to be useful in particular amongst the pediatric or geriatric population.... Janssen Pharmaceutica Nv

Imidazopyridazine derivatives as pi3kb inhibitors

wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds... Janssen Pharmaceutica Nv

Combination of canagliflozin and probenecid for the treament of hyperuricemia

The present invention is directed to methods for treating hyperuricemia and related disorders, comprising co-therapy with canagliflozin and probenecid.... Janssen Pharmaceutica Nv

Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes

wherein R1, R2, R3, R5, R6, W, and A are defined herein.... Janssen Pharmaceutica Nv

2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase

wherein the radicals are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such... Janssen Pharmaceutica Nv

1,2,4-triazolo[4,3-a]pyridine compounds and their use as positive allosteric modulators of mglur2 receptors

The present invention relates to novel 1,2,4-triazolo[4,3-a]pyridine compounds as positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for... Janssen Pharmaceutica Nv

P2x7 modulators

The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.... Janssen Pharmaceutica Nv

Antibodies to olanzapine haptens and use thereof

Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone... Janssen Pharmaceutica Nv

New pyrazole derivatives as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising... Janssen Pharmaceutica Nv

New compounds as nik inhibitors

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising... Janssen Pharmaceutica Nv

Trifluoromethyl alcohols as modulators of roryt

The present invention comprises methods of making 5-(2,3-dichloro-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-N-(2-hydroxy-2-methylpropyl)-4-(R1-1-carbonyl)thiazole-2-carboxamide, wherein R1 is defined in the specification.... Janssen Pharmaceutica Nv

Flap modulators

The present invention relates to compounds of Formula (I), or a form thereof wherein ring A, R1, L and R2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I)... Janssen Pharmaceutica Nv

Hiv replication inhibiting pyrimidines

the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing -a1=a2-a3=a4- and -b1=b2-b3=b4- represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl; n is 0 to 5; m is 1 to 4; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; substituted C1-6alkyl, C1-6alkylcarbonyl,... Janssen Pharmaceutica Nv

4-aminoquinazolin compounds as prolyl hydroxylase inhibitors

which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.... Janssen Pharmaceutica Nv

Macrocyclic quinazole derivatives and their use as mtki

Ar4 and Ar5 represents phenyl; Ar6 represents phenyl optionally substituted with nitro.... Janssen Pharmaceutica Nv

Anti-vista antibodies and fragments, uses thereof, and methods of identifying same

The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Compositions and methods of using anti-VISTA antibodies in combination with one or more antibodies that bind to immune checkpoint proteins... Janssen Pharmaceutica Nv

6-aminopyridin-3-yl thiazoles as modulators of roryt

The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one... Janssen Pharmaceutica Nv

4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs

The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.... Janssen Pharmaceutica Nv

Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor

Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as H4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.... Janssen Pharmaceutica Nv

Antibodies to paliperidone haptens and use thereof

Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, risperidone and... Janssen Pharmaceutica Nv

Antibodies to risperidone and use thereof

Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone... Janssen Pharmaceutica Nv

Gpr40 agonists in anti-diabetic drug combinations

wherein ring W, R1, R2, R3, R5, R6, A, and Z, are defined herein.... Janssen Pharmaceutica Nv

Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes

wherein U1, U2, U3, R1, R2, Z, and W are defined herein.... Janssen Pharmaceutica Nv

Inhibitors of bruton's tyrosine kinase and their use

The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).... Janssen Pharmaceutica Nv

Inhibitors of bruton's tyrosine kinase and their use

The present disclosure is directed to compounds of formula I′ and methods of their use and preparation, as well as compositions comprising compounds of formula I′.... Janssen Pharmaceutica Nv

6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for... Janssen Pharmaceutica Nv

6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for... Janssen Pharmaceutica Nv

A deuterated triazolopyridazine as a kinase modulator

The invention is directed to a triazolopyridazine compound of formula (I), N-oxides, pharmaceutically acceptable salts and solvates thereof, wherein D represents deuterium, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met... Janssen Pharmaceutica Nv

Alkyl linked quinolinyl modulators of rorγt

The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one... Janssen Pharmaceutica Nv

Methods of treating depression using orexin-2 receptor antagonists

The present disclosure is directed to, inter alia, methods of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 to R4 are described... Janssen Pharmaceutica Nv

Compositions containing ibrutinib

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia,... Janssen Pharmaceutica Nv

08/24/17 / #20170240653

Antibodies to olanzapine haptens and use thereof

Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone... Janssen Pharmaceutica Nv

08/17/17 / #20170233401

Substituted thiohydantoin derivatives as androgen receptor antagonists

wherein R1 and G are defined herein.... Janssen Pharmaceutica Nv

08/17/17 / #20170233479

Anti-vista antibodies and fragments, uses thereof, and methods of identifying same

The present invention relates to antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of eliciting certain biological responses using the antibodies. Methods of identifying anti-VISTA antibodies capable of eliciting certain biological responses are also included.... Janssen Pharmaceutica Nv

08/10/17 / #20170226089

Substituted 1,2,3-triazoles as nr2b-selective nmda modulators

Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.... Janssen Pharmaceutica Nv

08/03/17 / #20170215766

Sensor device and carriers

Disclosed herein are systems comprising sensor devices that may be affixed to a patient and used to perform clinical measurements such as measurements for calculating a BASMI score. A first sensor device is configured to be successively attached to each of a wrist carrier, an ankle carrier, and a headset... Janssen Pharmaceutica Nv

08/03/17 / #20170217971

6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for... Janssen Pharmaceutica Nv

08/03/17 / #20170217972

6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for... Janssen Pharmaceutica Nv

08/03/17 / #20170218466

Detection of circulating jc polyomavirus (jcpyv) micrornas as biomarker for jcpyv infection

The invention concerns the quantitative analysis of circulating JCPyV microRNAs (miRNA) in body fluid and its use as biomarker for JCPyV infection.... Janssen Pharmaceutica Nv

07/20/17 / #20170204096

Substituted 2-azabicycles and their use as orexin receptor modulators

wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or O; R3 is H, alkyl, alkoxy, halo, or triazolyl; R4 is H or alkyl; or R3... Janssen Pharmaceutica Nv

07/20/17 / #20170204198

Antibodies to aripiprazole haptens and use thereof

Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone... Janssen Pharmaceutica Nv

07/13/17 / #20170198357

R2r1/2 in diagnosis and therapy

The present invention stems from the finding that two genes designated R2R1 and R2R2, play important roles in tissue development and cancer biology. In particular, the inventors have discovered that these two genes are expressed in pulmonary cells and are required for late branching morphogenesis of pulmonary epithelium and endothelium... Janssen Pharmaceutica Nv

07/06/17 / #20170192016

N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses

This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta_11 N-terminal site, i.e. Aβ11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices.... Janssen Pharmaceutica Nv

06/29/17 / #20170182056

Quinolinyl modulators of roryt

The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one... Janssen Pharmaceutica Nv

06/22/17 / #20170173014

Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1h-imidazo[1,2-b]pyrazole derivatives as ros1 inhibitors

wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds... Janssen Pharmaceutica Nv

06/22/17 / #20170174680

P2x7 modulators

The invention also relates to pharmaceutical compositions comprising compounds of Formula (I) or (Ia). Methods of making and using the compounds of Formula (I) or (Ia) are also within the scope of the invention.... Janssen Pharmaceutica Nv

06/22/17 / #20170174690

Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-a][1,4]diazepine derivatives as ros1 inhibitors

wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds... Janssen Pharmaceutica Nv

06/22/17 / #20170176473

Antibodies to risperidone and use thereof

Disclosed is an antibody or a binding fragment thereof that binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody or fragment thereof can be used in a lateral flow assay device for point-of-care detection of risperidone, including... Janssen Pharmaceutica Nv

06/22/17 / #20170176474

Antibodies to quetiapine and use thereof

Disclosed is an antibody or a binding fragment thereof which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody or the fragment thereof can be used in a lateral flow assay device for point-of-care detection of quetiapine,... Janssen Pharmaceutica Nv

06/15/17 / #20170164630

Milk filtration devices and methods for filtering

A method of cleaning mother's milk, involving ex vivo contacting mother's milk having an initial concentration of an antidepressant therein with a solid substrate (preferably a porous substrate) adapted to remove the antidepressant from the milk to produce a cleansed milk product having a reduced concentration of the antidepressant.... Janssen Pharmaceutica Nv

06/08/17 / #20170158673

Quinazolinone derivatives as parp inhibitors

wherein R1, R2, R3, L, X, Y and Z have defined meanings.... Janssen Pharmaceutica Nv

06/08/17 / #20170158678

Substituted pyridine derivatives useful as c-fms kinase inhibitors

The present invention is directed to substituted pyridine derivatives, pharmaceutical compositions containing said derivatives and the use of said derivatives in the treatment of disorders mediated by c-fms kinase. The present invention is further directed to a process for the preparation of said substituted pyridine derivatives.... Janssen Pharmaceutica Nv

05/11/17 / #20170128451

Dosing regimen associated with long acting injectable paliperidone esters

The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.... Janssen Pharmaceutica Nv

05/11/17 / #20170129901

Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators

Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.... Janssen Pharmaceutica Nv

05/11/17 / #20170129968

Antibodies to paliperidone haptens and use thereof

Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, risperidone and... Janssen Pharmaceutica Nv

05/04/17 / #20170121292

Hiv replication inhibiting pyrimidines

the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing -a1=a2-a3=a4- and -b1=b2-b3=b4- represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl; n is 0 to 5; m is 1 to 4; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; substituted C1-6alkyl, C1-6alkylcarbonyl,... Janssen Pharmaceutica Nv

05/04/17 / #20170121309

Substituted 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same

The present invention relates to certain intermediates useful in the preparation of certain benzoimidazol-2-yl pyrimidines and processes for preparing them. In particular, the present invention relates to various 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides as useful intermediates in the preparation of compounds including... Janssen Pharmaceutica Nv

05/04/17 / #20170121420

Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof

Provided herein are antibodies that specifically bind to IL1RAP. Also described are related polynucleotides capable of encoding the provided IL1RAP-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the... Janssen Pharmaceutica Nv

04/27/17 / #20170112806

Pharmaceutical formulations

or prodrug, or a pharmaceutically acceptable salt thereof.... Janssen Pharmaceutica Nv

04/27/17 / #20170112818

Inhibitors of the interaction between mdm2 and p53

wherein n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, R20, X, Y, Q and Z have defined meanings.... Janssen Pharmaceutica Nv

04/06/17 / #20170095403

Vial holder devices and systems

A packaging system is provided for securely and irreversibly holding a sterile product. The packaging system includes a primary packaging holder and a secondary packaging holder. The secondary packaging holder has a body made up of a top having a receiving portion configured to receive the primary packaging holder, a... Janssen Pharmaceutica Nv

Patent Packs
03/30/17 / #20170088531

Benzo-fused heterocyclic derivatives useful as agonists of gpr120

The present invention is directed to benzo-fused heterocyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GPR120. More particularly, the compounds of the present invention are agonists of GPR120, useful in the treatment of, such as for example, Type II diabetes... Janssen Pharmaceutica Nv

03/16/17 / #20170071970

Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the... Janssen Pharmaceutica Nv

03/16/17 / #20170072061

Haptens of aripiprazole

The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from aripiprazole. The invention also relates to conjugates of an aripiprazole hapten and a protein.... Janssen Pharmaceutica Nv

03/16/17 / #20170073348

Novel antifungal 5,6-dihydro-4h-pyrrolo[1,2-a][1,4]benzo-diazepines and 6h-pyrrolo[1,2-a][1,4]benzodiazepines substituted with heterocyclic derivatives

wherein R1, R2, R3, R4 and Het have the meaning defined in the claims. The compounds according to the present invention are active mainly against dermatophytes and systemic fungal infections. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient... Janssen Pharmaceutica Nv

03/09/17 / #20170066760

Therapeutic compounds and synthesis

or a stereoisomer, pharmaceutically acceptable salt, or mixture thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.... Janssen Pharmaceutica Nv

03/09/17 / #20170066767

Therapeutic compounds for pain and synthesis thereof

and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.... Janssen Pharmaceutica Nv

03/09/17 / #20170066768

Therapeutic compounds for pain and synthesis thereof

and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.... Janssen Pharmaceutica Nv

03/09/17 / #20170066769

Therapeutic compounds for pain and synthesis thereof

and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of making and using such compounds. The invention includes pharmaceutical compositions containing such compounds, and the use of such compounds in methods of treating conditions, diseases, or disorders.... Janssen Pharmaceutica Nv

03/09/17 / #20170066770

Therapeutic compound for pain and synthesis thereof

wherein R1 is hydrogen, alkyl, acyl, or silyl, R2 is hydrogen, alkyl, benzyl, acyl, or ester, and R3 is hydrogen, alkyl, an aromatic group, azacyclic, carbocycle, aryl, cycloalkyl, heterocycloalkyl, heterocycle, heteroaryl, heteroalkyl, acyl, or ester, as well as derivatives and stereoisomers, pharmaceutically acceptable salts and derivatives thereof; and methods of... Janssen Pharmaceutica Nv

03/02/17 / #20170057919

Process for the preparation of histamine h3 receptor modulators

The present invention is directed to novel processes for the preparation of histamine H3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.... Janssen Pharmaceutica Nv

03/02/17 / #20170057922

Chemically modified quinoline and quinolone derivatives useful as cb-1 inverse agonists

wherein the group “X═Y”, ring A, R10, R11, R30, W, and t are defined herein.... Janssen Pharmaceutica Nv

03/02/17 / #20170057925

Indazole derivatives useful as cb-1 inverse agonists

The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of... Janssen Pharmaceutica Nv

03/02/17 / #20170057929

Benzimidazole derivatives useful as cb-1 inverse agonists

The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of... Janssen Pharmaceutica Nv

03/02/17 / #20170059568

Identification of jc viral epitopes by cytotoxic t lymphocytes in healthy individuals and their use in assays

The invention relates to a method to predict the onset and/or development of PML in a patient or in an immunosuppressed patient by detection of JCV specific CTL's in blood of said patient using any of the ten (10) JCV amino acid sequences SEQ ID NO 1-10 separately or in... Janssen Pharmaceutica Nv

02/23/17 / #20170051061

Anti-vista antibodies and fragments

The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.... Janssen Pharmaceutica Nv

Patent Packs
02/23/17 / #20170051068

Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof

Provided herein are antibodies that immunospecifically bind to BCMA. Also described are related polynucleotides capable of encoding the provided BCMA-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the... Janssen Pharmaceutica Nv

02/16/17 / #20170044146

Gpr40 agonists for the treatment of type ii diabetes

wherein R1, R2, R4, W, X, Y, and G, are defined herein.... Janssen Pharmaceutica Nv

02/16/17 / #20170044147

Gpr40 agonists for the treatment of type ii diabetes

wherein R1B, R2B, R4B, WB, XB, YB, and GB, are defined herein.... Janssen Pharmaceutica Nv

02/16/17 / #20170044148

Gpr40 agonists for the treatment of type ii diabetes

wherein R1C, R2C, R4C, WC, YC, ZC, and GC, are defined herein.... Janssen Pharmaceutica Nv

02/16/17 / #20170045504

Channel for trapping particles to be fed to said channel with a fluid

The invention relates to a channel for trapping particles to be fed to the channel with a fluid. The invention further relates to a flow cell comprising such a channel. The invention also relates to an assembly comprising such a flow cell and a detection means. The invention also relates... Janssen Pharmaceutica Nv

02/16/17 / #20170045537

Antibodies to paliperidone and use thereof

Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone/paliperidone... Janssen Pharmaceutica Nv

02/09/17 / #20170037152

Antibodies to olanzapine and use thereof

Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone... Janssen Pharmaceutica Nv

02/02/17 / #20170029381

Tetrahydro-benzoimidazolyl modulators of tgr5

R1, R2, R3, R4, R5, R6, R7, R8, X, Z1 and Z2 are defined in the specification.... Janssen Pharmaceutica Nv

02/02/17 / #20170029440

Piperidine/piperazine derivatives

The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.... Janssen Pharmaceutica Nv

02/02/17 / #20170030936

Antibodies to aripiprazole and use thereof

Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone... Janssen Pharmaceutica Nv

01/26/17 / #20170022201

Macrocylic pyridine derivatives

wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as... Janssen Pharmaceutica Nv

01/26/17 / #20170022202

Macrocylic pyrimidine derivatives

wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as... Janssen Pharmaceutica Nv

01/19/17 / #20170015651

Substituted 2-azabicycles and their use as orexin receptor modulators

wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or O; R3 is H, alkyl, alkoxy, halo, or triazolyl; R4 is H or alkyl; or R3... Janssen Pharmaceutica Nv

01/12/17 / #20170008890

Substituted 4-azaindoles and their use as glun2b receptor modulators

Substituted 4-azaindoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.... Janssen Pharmaceutica Nv








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Janssen Pharmaceutica Nv in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Janssen Pharmaceutica Nv with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###